Monoclonals to SARS-CoV-2

Meridian’s antibodies are highly sensitive for the detection of SARS-CoV-2 and they are ideal for developing reliable and sensitive rapid antigen assays for the detection of active COVID-19 infections. Meridian has a novel antibody pair to trimeric SARS-CoV-2 S1 protein that is capable of recognizing the spike 1 (S1) protein in saliva samples regardless of its confirmation state (e.g. “up” or “down”). The antibodies bind to a linear epitope on the S1 protein that is distinct from the RBD protein which has epitopes that are conformation-dependent. Recent studies have shown that linear epitopes on the S1 protein are able to elicit neutralizing antibodies in COVID-19 patients and have potent antigenicity, making them prime targets for diagnostic, therapeutic, and vaccine targets. Li, Y., Lai, D., Zhang, H. et al. Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patients. Cell Mol Immunol (2020).

MAbs to Nucleocapsid Protein

Antibodies work as a pair and are suitable for use in ELISA, Lateral Flow and Western Blot. They are capable of detects the SARS-CoV-2 variant strains Alpha B.1.1.7, Beta B.1.351, Gamma P.1/P.2 and Delta B.1.617.2. They do not cross react with any other coronavirus except SARS-CoV.

Nucleocapsid Protein (Capture MAb)

Nucleocapsid Protein (Detection MAb)

Nucleocapsid Protein (Alternate Detection MAb)

MAbs to Trimeric Spike Protein

Antibodies work as a pair and can detect SARS-CoV-2 trimeric spike protein down to ~300 pg/mL by using TMB substrate in ELISA assay. They bind to a linear epitope and are not conformation dependent. They are suitable for ELISA, Lateral Flow and Western Blot applications and they can be used as a positive control antibody in neutralizing assays with Meridian’s SARS-CoV-2 Spike mutant recombinant antigens.